FindTrial
Sign In

Add long-acting insulin or premixed insulin after oral antidiabetic drugs failing to reach HbA1c target: a randomized, cross-over trial

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: a randomized, cross-over trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020301
Enrollment
Unknown
Registered
2018-12-22
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

IGlar Group:Glargine - Asp30
Asp30 Group:Asp30-IGlar

Sponsors

The Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes taking 2 or more oral anti diabetic drugs for more than 3 months; 2. Aged 18-75 years old; 3. HbA1c 7.5%~11.0%; 4. FBG>7.0 mmol/L.

Exclusion criteria

Exclusion criteria: 1. Type1 diabetes; 2. Pregnant; 3. Patients with tumor; 4. Taking corticoid hormone.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;Hemoglobin A1c;—

Countries

China

Contacts

Public ContactLi Wangen

The Second Affiliated Hospital of Guangzhou Medical University

liwg660@126.com+86 18926298645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026